Browse studies

Find your next paid study

7 recruiting studies matching your filters

Phase 1B/2A Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy

This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). Th…

Cytokine Release Syndrome

Estimated

~$10 – $8,750

CytoAgents, Inc.NCT05905328

Phase 1

Pilot Study of Pre-emptive Anakinra for the Prevention of Severe Cytokine Release Syndrome in Children and Young Adults With B-Acute Lymphoblastic Leukemia Receiving Chimeric Antigen Receptor (CAR) T Cells

Objectives: The primary objective of this study will be to evaluate the impact of pre-emptive use of anakinra on the rate of severe cytokine release syndrome (…

B-Acute Lymphoblastic LeukemiaCAR-T Cell TherapyCytokine Release Syndrome+2 more

Estimated

~$10 – $7,500

Kevin McNerneyNCT06703216

Phase 2

Phase 2 Study of Cytokine Release Syndrome Prophylaxis With Infliximab for Teclistamab/Talquetamab Therapy in Patients With Relapsed/Refractory Myeloma

This phase II trial tests how well giving infliximab works for the prevention of cytokine release syndrome (CRS) during treatment with teclistamab or talquetam…

Cytokine Release SyndromeRecurrent Multiple MyelomaRefractory Multiple Myeloma

Estimated

~$10 – $7,500

Naresh BummaNCT07657312

Phase 1

Pilot Safety-feasibility Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

The goal of this clinical trial is to is to determine the safety, feasibility and efficacy of siltuximab prophylaxis of cytokine release syndrome and neurotoxi…

Non-Hodgkin LymphomaCytokine Release Syndrome

Estimated

~$10 – $7,500

Taylor BrooksNCT06447376

Observational

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

The proposed multimodal telerehabilitation model allows a rehabilitation therapy team to set up individualized rehabilitation plans using a web-based care mana…

LymphomaMyelomaCytokine Release Syndrome+1 more

Estimated

~$10 – $6,250

University of UtahNCT07390071

Phase 1

Pilot, Open-Label Study Evaluating the Safety and Feasibility of Using Rescue Therapies for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome

This is a pilot, open-label study to assess the safety and feasibility of using investigational drug(s) as rescue therapies for CAR T cell related CRS and HLH-…

CRS - Cytokine Release SyndromeHLH

Estimated

~$10 – $6,250

University of PennsylvaniaNCT05306080

Observational

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

Background: Drugs or cell therapies to treat cancer can sometimes cause cytokine release syndrome (CRS). That is, the body makes too many cytokines after trea…

Cytokine Release SyndromeNeoplasmsLymphoma+13 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07499128